Clinical Trials List
2018-12-13 - 2020-12-09
Phase III
Terminated4
ICD-10L20.0
Besnier's prurigo
ICD-10L20.81
Atopic neurodermatitis
ICD-10L20.82
Flexural eczema
ICD-10L20.83
Infantile (acute) (chronic) eczema
ICD-10L20.84
Intrinsic (allergic) eczema
ICD-10L20.89
Other atopic dermatitis
ICD-10L20.9
Atopic dermatitis, unspecified
ICD-9691.8
Other atopic dermatitis and related conditions
A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
-
Trial Applicant
AbbVie
-
Sponsor
AbbVie
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Yu-Chen Huang Division of Dermatology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Chih-Chieh Chan Division of Dermatology
- WEI-HSIN WU Division of Dermatology
- 卓雍哲 Division of Dermatology
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
The primary endpoint is the proportion of subjects achieving a 75% reduction in EASI (EASI 75) from
Baseline at Week 16.
Inclution Criteria
Participant has active moderate to severe atopic dermatitis (AD) defined by Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Body Surface Area (BSA) and pruritus.
Participant is a candidate for systemic therapy or have recently required systemic therapy for AD.
Exclusion Criteria
Participant has prior exposure to Janus Kinase (JAK) inhibitor.
Participant has prior exposure to dupilumab.
Participant is unable or unwilling to discontinue current AD treatments prior to the study.
Participant has requirement of prohibited medications during the study.
Participant has other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of AD lesions.
Female participant who is pregnant, breastfeeding, or considering pregnancy during the study.
The Estimated Number of Participants
-
Taiwan
40 participants
-
Global
650 participants
